In the trial, adults with prediabetes and obesity or who were overweight with comorbidities were randomised to receive liraglutide (n=1505) or placebo (n=749) for 160 weeks, both as an adjunct to a reduced-calorie diet and increased physical activity. Participants were categorised according to baseline BMI as overweight or class 1–3 obese. All four categories had consistent weight loss at 3 years compared with placebo, with mean weight loss ranging from 5.7% to 6.5% compared with 1.8% to 2.1% in placebo recipients.
The proportion of individuals who reverted to normal blood glucose levels on liraglutide was also similar across the four categories, ranging from 63% to 70%, and significantly greater compared with placebo (33–40%). In addition, improvements in a number of measures of glycaemic control were observed compared with placebo.
More details on the study can be read here.
